To explore relationships between erection hardness and other outcomes in men with erectile dysfunction (ED). Pooled analyses were conducted on 27 randomized, double-blind, placebocontrolled trials and six open-label trials from the worldwide sildenafil database. Outcomes included erection hardness graded subjectively, hardness and sexual satisfaction questions from the International Index of Erectile Function, general and sexually-specific emotional well-being from the self-esteem and relationship questionnaire, and the erectile dysfunction inventory of treatment satisfaction. Hardness outcomes improved (with a possible dose-response relationship for the achievement of fully hard and rigid erections) and correlated positively with the other outcomes. Sildenafil 100 mg produced optimal erection hardness (fully hard and rigid erections) in a substantial proportion of men with ED. Because optimal erection hardness correlated positively with some emotional well-being and satisfaction outcomes, sildenafil 100 mg may be the most appropriate dosage for treatment of ED for most men.
Introduction
Erection hardness is a fundamental component of erectile function and is a very specific and easily monitored outcome. A survey of more than 3500 men with erectile dysfunction (ED) worldwide established that the primary attribute sought in a treatment for ED is that it enables hard erections. 1 In studies of erection hardness measured objectively using penile tumescence monitoring (RigiScan, Dacomed, Minneapolis, MN, USA) or graded subjectively at the time of erection with a singleitem patient-reported outcome, most men treated with sildenafil citrate (Viagra, Pfizer Inc, New York, NY, USA) for ED rapidly achieved increased erection hardness, achieved an erection that they characterized as hard enough for penetration (e.g., grade 3) or fully hard and rigid (e.g., grade 4), and had erection hardness that persisted several-fold longer than that achieved by men with ED who took placebo. [2] [3] [4] [5] [6] The real-world effectiveness and patient acceptance of a treatment is dependent upon its ability to improve function and upon other outcomes such as satisfaction and effect on emotional well-being. Using the large database of phase II, III and IV clinical research conducted worldwide on sildenafil treatment for ED, Montorsi et al. 7 determined that improvements in erectile function and in outcomes assessing erection hardness correlated positively with outcomes on certain assessments of sexual satisfaction (i.e., sexual intercourse satisfaction, frequency of satisfactory intercourse and satisfaction with sex life and sexual relationship) assessed with the International Index of Erectile Function (IIEF), emotional well-being in general and specific to sexual activity (i.e., self-esteem and confidence) assessed with the Self-Esteem And Relationship (SEAR) questionnaire, and ED treatment satisfaction assessed with the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS).
To expand understanding of the relationship between erection hardness and outcomes assessing emotional well-being and satisfaction in men treated with sildenafil for ED, we update the report of Montorsi et al., 7 providing additional post hoc analyses of individual and pooled clinical trial data. A strong relationship would suggest effectiveness across this broad spectrum of outcomes when erection hardness was increased.
Methods

Design
The pertinent data on assessments of erection hardness and of emotional well-being and satisfaction outcomes were collected from trials included in the large database of sildenafil phase II, III and IV clinical research conducted worldwide. Twentyseven of the trials were randomized, double-blind and placebo-controlled (26 flexible-dose and one fixed-dose); six were open-label. 7 Patients were men in a stable, sexual relationship who had ED that was clinically documented according to the criteria of the National Institutes of Health Consensus Conference guidelines 8 or with the Sexual Health Inventory for Men. 9 The minimum age for inclusion was 18 years in all trials except for a European trial of men with ED and type II diabetes (minimum age, 37 years). 10 Exclusion criteria included hypotension (p90/50 mm Hg) or hypertension (X170/110 or X180/110 mm Hg); significant cardiovascular disease; or taking nitrates, nitric oxide donors or ritonavir. 7 The trials were approved by appropriate local independent review boards and were conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent.
Except for one large double-blind, placebo-controlled trial of fixed-dose sildenafil 25, 50 and 100 mg, 11, 12 all of the trials assessed flexible-dose sildenafil (25, 50 and 100 mg). 7 The recommended starting dose for sildenafil is 50 mg, which may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg based on effectiveness and tolerability. Patients were instructed to take trial medication approximately 1 h before anticipated sexual activity but not more than once daily.
Assessments and outcomes
Hardness was assessed subjectively, at the time of the erection and retrospectively at baseline and at the end of treatment (Table 1) . At the time of sexual activity, the men used the Erection Hardness Score (EHS), a single-item, patient-reported outcome on the patient event log, to characterize their erection hardness as 'increase in size but not hard' (grade 1); 'hard but not hard enough for penetration' (grade 2); 'hard enough for penetration (but not completely hard)' (grade 3); or 'completely hard' (grade 4). 5 At baseline and at the end of treatment, they retrospectively assessed their erection hardness according to IIEF Q2 and their ability to penetrate and maintain erections according to IIEF Q3 and Q4, respectively. 13 They also retrospectively assessed their erection hardness at the end of treatment according to EDITS Q11. Q5: I was likely to initiate sex Q6: I felt confident about performing sexually Q7: I was satisfied with our sex life Q8: My partner was unhappy with the quality of our sexual relations
14
Confidence domain
Self-esteem subscale Q9: I had good self-esteem Q10: I felt like a whole man Q11: I was inclined to feel that I am a failure Q12: I felt confident Overall relationship subscale Q13 My partner was satisfied with our relationship in general Q14: I was satisfied with our relationship in general Overall score 
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The men retrospectively assessed their emotional well-being (general and sexually specific), sexual satisfaction, overall relationship satisfaction and satisfaction with their ED treatment using the SEAR questionnaire 15 and individual unvalidated questions of the IIEF 13 and the EDITS 14 ( Table 1 ). The IIEF, SEAR and EDITS are psychometrically sound questionnaires with established validity and reliability. [13] [14] [15] Outcomes included the change from baseline to end of treatment in percentage of erections of each hardness grade, in IIEF question scores and in SEAR component scores; end-of-treatment scores for EDITS questions; and correlations between outcomes assessing hardness and outcomes assessing emotional well-being and satisfaction.
Statistics
Data from trials that collated the analysis variables and had similar trial design were pooled. Correlation was determined via Pearson correlation coefficients for outcomes assessing hardness (hardness grade: IIEF Q2, Q3 and Q4; and EDITS Q11) with outcomes assessing sexual confidence, enjoyment and satisfaction (i.e., IIEF questions), emotional well-being (i.e., SEAR components), overall relationship satisfaction (i.e., SEAR Overall Relationship subscale) and treatment satisfaction (i.e., EDITS questions).
Descriptive statistics (mean7s.d.) were used to summarize the percentage occasions of erections of each hardness grade and the scores for IIEF questions, SEAR components and EDITS questions.
Results
Correlation of fully hard erections (Grade 4) and IIEF sexual enjoyment and satisfaction questions Two double-blind, placebo-controlled trials included erection hardness grades and the IIEF. The first was a fixed-dose trial (24 weeks of treatment), conducted in the United States, in which 532 men (mean age, 58 years; range, 20-87 years) were randomized to receive sildenafil (25, 50 or 100 mg) or placebo. 11, 12 The second was a flexible-dose trial (12 weeks of treatment), which was conducted in the United Kingdom (and is also part of a 26-trial pool described in the next section); it included 111 men (mean age, 55 years; range, 29-89 years). 16 In the fixed-dose trial, men who received sildenafil 100 mg reported grade 4 erections eightfold more often at the end of treatment (34.4%) than at baseline (4.4%), compared with a fivefold increase in men who received sildenafil 50 mg (30.4 vs 6.2%), a sixfold increase in men who received sildenafil 25 mg (21.2 vs 3.5%) and no change in men who received placebo (4.9 vs 4.7%). The proportion of men taking sildenafil 100 mg who shifted to having grade 4 erections most frequently at the end of treatment was 30% in those whose most frequent baseline grade was 1, was 38% in those whose most frequent baseline grade was 2 and was 76% in those whose most frequent baseline grade was 3 ( Figure 1 ). Corresponding percentages of men with a most frequent end-of-treatment grade of 4 were 41, 21 and 58%, respectively, for those who took sildenafil 50 mg and 15, 19 and 38%, respectively, for those who took sildenafil 25.
For the correlation analyses of the percentage of grade 4 (fully hard) erections during the last 4 weeks of treatment vs end-of-treatment scores for IIEF sexual enjoyment and satisfaction questions, almost all correlations were positive. The correlation coefficient ranged from 0.33 to 0.50, overall, in the trial of flexible-dose sildenafil, with values for the intercourse enjoyment item (IIEF Q8, 0.33) and for the sexual relationship satisfaction item (IIEF Q14, 0.38) at the lower end of the range (Table 2 ). In men who took placebo, the correlation coefficient ranged from 0.01 to 0.45 (data not shown). The correlation coefficients ranged from 0.21 to 0.60, overall, in the trial of fixed-dose sildenafil, with the highest values (0.49-0.60) for sildenafil 100 mg (Table 2 ). In men who took placebo, the correlation coefficient ranged from 0.20 to 0.28 (data not shown).
Correlation of IIEF hardness questions and emotional well-being and satisfaction assessments Two post hoc analyses were conducted for a pool (sildenafil, n ¼ 3261; placebo, n ¼ 2883) from 26 double-blind, placebo-controlled trials that included the IIEF 1, 10, 11, and for a subpool (sildenafil, n ¼ 279; placebo, n ¼ 274) from two trials that Correlations with erection hardness R King et al had identical protocols, included the IIEF, and also included the SEAR questionnaire. 1, 17, 37, 38 In both pools, the mean patient age was 55 years, ED was mostly of organic or mixed etiology, and baseline characteristics, assessments of hardness and other assessments were similar between the men randomized to sildenafil and those randomized to placebo. 7 In the 26-trial pool, the proportion of men who scored 4 (most times, much more than half the time) or 5 (almost always/always) on IIEF Q2 (frequency of erection hard enough for penetration) at the end of treatment was 49% in flexible-dose sildenafil recipients vs 12% in placebo recipients in the subgroup with a baseline IIEF Q2 score of 1 (almost never/never), 75 vs 25% in the subgroup with a baseline score of 2 (a few times, much less than half the time) and 79 vs 40% in the subgroup with a baseline score of 3 (sometimes, about half the time). Score shifts for IIEF Q3 (frequency of penetration) and Q4 (frequency of maintaining erection after penetration) were similar to those for IIEF Q2, with comparable differences between men who took flexible-dose sildenafil and men who took placebo (Figure 2) .
In men randomized to sildenafil, the change from baseline to end of treatment in mean scores for IIEF hardness questions (Q2, Q3 and Q4) correlated positively with the change from baseline to end of treatment in mean scores for IIEF sexual confidence, enjoyment and satisfaction questions (Q7, frequency of satisfactory intercourse; Q8, intercourse enjoyment; Q13, sex life satisfaction; Q14, sexual relationship satisfaction; and Q15, confidence in erection ability). The correlation coefficients ranged from 0.50 to 0.77 overall but the lowest values occurred for the sexual relationship satisfaction item (Q14, 0.50-0.53) ( Table 3 ). In men who took placebo, the correlation coefficient ranged from 0.43 to 0.68 (data not shown).
In the sildenafil group compared with the placebo group of the two-trial subpool, mean scores across the 5 SEAR components improved 28-37 points (n ¼ 257) vs 9-14 points (n ¼ 255) overall, and improved -1-16 points (n ¼ 17) vs 18-27 points Correlations with erection hardness R King et al 70 years or older. 1 The change from baseline to end of treatment in mean scores for IIEF Q2, Q3 and Q4 correlated positively with the change from baseline to end of treatment in mean scores for SEAR components. For these analyses of outcomes on IIEF hardness questions vs SEAR components, the correlation coefficient ranged from 0.47 to 0.64 (Table 3) .
Correlation of EDITS hardness and treatment satisfaction questions
The EDITS, which was only administered at the end of treatment, was included in six open-label trials of sildenafil treatment of men with ED, which included 2640 men who completed the EDITS questionnaire (mean age, 53.770.2 years; range, 18-96 years), 1, 39 EDITS items are scored from 0 (lowest satisfaction) to 4 (highest satisfaction) and the EDITS index is derived by multiplying the mean score by 25. Overall, 86% (2265/2625) who completed the EDITS were satisfied with sildenafil treatment (defined as an EDITS Index 450), including 89% p60 years and 78% 460 years. At the end of treatment, the mean7s.d. score for the EDITS erection hardness question (Q11) was 2.4470.02, indicating the same or better hardness as before the patient's erection problem. (Table 4) . Correlations with erection hardness R King et al
Discussion
This report updated the report of Montorsi et al., 7 who had determined previously that improvements in erectile function and in outcomes assessing erection hardness correlated positively with outcomes on certain assessments of sexual satisfaction (i.e., sexual intercourse satisfaction, frequency of satisfactory intercourse, and satisfaction with sex life and sexual relationship) assessed with the IIEF, emotional well-being (i.e., self-esteem and confidence) assessed with the SEAR questionnaire and ED treatment satisfaction assessed with the EDITS. The current results show that outcomes on several assessments of erection hardness improved in men treated with sildenafil for ED. In response to IIEF questions about the frequency of hardness sufficient for penetration, frequency of erections that enabled penetration and frequency of erections that were maintained after penetration, an end-of-treatment frequency of 'most times (much more than half the time)' or 'almost always/always' was reported by approximately 2-4 times as many men treated with sildenafil compared with placebo in the subgroups whose baseline frequency was 'sometimes (about half the time)' to 'almost never/never.' According to outcomes on the EDITS hardness question, sildenafil treatment was associated, on average, with the same or better hardness as before the man's erection problem developed. There was some evidence of a possible dose response to sildenafil treatment such that, among men whose most frequent erection hardness grade at baseline was 'ysufficient for sexual intercourse but not fully hard (rigid),' 58% treated with 50 mg compared with 76% treated with 100 mg improved to a most frequent erection hardness grade of 'fully hard (rigid).' Similarly, the percentage of erections graded fully hard and rigid increased fivefold in men treated with sildenafil 50 mg and increased eightfold in men treated with sildenafil 100 mg. Thus, sildenafil treatment of men for ED improved outcomes on assessments of hardness, with a possible dose response favoring the 100-mg dose in the achievement of fully hard and rigid erections. Sildenafil 100 mg is generally well tolerated, and previously reported data showed that this dose was preferred over sildenafil 50 mg by the majority of men in the pooled analysis of 26 double-blind, placebo-controlled trials, overall and in the subgroup of men with mild ED. 40 The association between outcomes assessing emotional well-being, satisfaction and erection hardness in men treated with sildenafil for ED is supported by positive correlations. From baseline to end of treatment, the change in outcomes on assessments of intercourse enjoyment, sexual satisfaction (i.e., frequency of satisfactory intercourse, and satisfaction with sex life and sexual relationship), confidence (in erection ability and overall) and self-esteem correlated positively with the change in the frequencies of erections that were hard enough for penetration, erections that enabled penetration and erections that were maintained after penetration. Also, from baseline to end of treatment, the change in outcomes on assessments of sexual relationship and overall relationship satisfaction correlated positively with the change in frequency of erections that were hard enough for penetration. End-of-treatment outcomes on assessments of intercourse enjoyment and sexual satisfaction correlated positively with the percentage of erections graded completely hard and fully rigid during the last 4 weeks of treatment. Also, end of treatment assessment of satisfaction with the ED treatment (satisfaction with speed of onset, satisfaction with duration of action and satisfaction with treatment overall) correlated positively with the assessment of naturalness of the erection in terms of hardness. Thus, improvement in outcomes assessing erection hardness in men treated with sildenafil for ED was associated with improvement in outcomes assessing intercourse enjoyment, sexual satisfaction, emotional well-being and satisfaction with the ED treatment.
Conclusions
These results in men with ED show that sildenafil treatment improved outcomes assessing erection hardness, with a possible dose-response relationship observed for the achievement of fully hard and rigid erections. Improvement in outcomes assessing erection hardness was associated with improvement in outcomes assessing intercourse enjoyment, sexual satisfaction (i.e., frequency of satisfactory intercourse, and satisfaction with sex life and sexual relationship), emotional well-being (self-esteem, relationship, and confidence in erection ability and overall) and satisfaction with the ED treatment. The positive correlations between erections graded completely hard and fully rigid and outcomes assessing intercourse enjoyment and sexual satisfaction suggest that completely hard and fully rigid erections may be the appropriate goal of ED treatment. In addition, the possible dose response to sildenafil treatment and the achievement of optimal erection hardness (fully hard and rigid erections) in a substantial proportion of men treated with sildenafil 100 mg for ED suggest that 100 mg may be the most appropriate dose of sildenafil to achieve the goal of fully hard and rigid erections for most men. 
